Skip to main content
SpringerLink
Log in

G-CSF cost-neutral for early-stage breast cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

G-CSF cost-neutral for early-stage breast cancer. Pharmacoecon. Outcomes News 646, 9 (2012). https://doi.org/10.1007/BF03272345

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03272345

Keywords

Search

Navigation